- Home
- CB vs PFE Comparison
CB vs PFE Comparison
Compare CB & PFE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CB | PFE |
|---|---|---|
| Founded | 1985 | 1849 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 127.9B | 147.6B |
| IPO Year | 1995 | 2013 |
Fundamental Metrics
Financial Performance| Metric | CB | PFE |
|---|---|---|
| Price | $335.19 | $24.08 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 21 | 14 |
| Target Price | ★ $332.76 | $29.29 |
| AVG Volume (30 Days) | 1.6M | ★ 29.6M |
| Earning Date | 04-21-2026 | 05-05-2026 |
| Dividend Yield | 1.19% | ★ 6.55% |
| EPS Growth | ★ 13.13 | N/A |
| EPS | ★ 5.88 | 0.47 |
| Revenue | $59,402,000,000.00 | ★ $62,579,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $5.31 | N/A |
| P/E Ratio | $56.49 | ★ $52.61 |
| Revenue Growth | ★ 6.54 | N/A |
| 52 Week Low | $264.10 | $23.11 |
| 52 Week High | $345.67 | $28.75 |
Technical Indicators
Market Signals| Indicator | CB | PFE |
|---|---|---|
| Relative Strength Index (RSI) | 61.71 | 27.62 |
| Support Level | $317.41 | $23.96 |
| Resistance Level | $345.67 | $26.42 |
| Average True Range (ATR) | 6.73 | 0.52 |
| MACD | 1.17 | -0.14 |
| Stochastic Oscillator | 89.74 | 4.68 |
Price Performance
Historical ComparisonAbout CB Chubb Limited
ACE acquired Chubb in 2016 and assumed the Chubb name. The combination made the new Chubb one of the largest domestic property and casualty insurers, with operations in over 50 countries spanning commercial and personal P&C insurance, reinsurance, and life insurance.
About PFE Pfizer Inc.
Pfizer is one of the world's largest pharmaceutical firms, with annual sales of roughly $60 billion. While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13 and cardiology drugs Vyndaqel and Eliquis. Pfizer sells these products globally, with international sales representing 40% of total sales. Within international sales, emerging markets are a major contributor.